🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 2 of 757 · Phase 3 first, then by program name

  1. 0.2 mg/kg ketamine

    United Therapeutics Europe Ltd

    Depression

    phase 3 small molecule terminated

    1 trial

  2. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  3. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  4. 0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

    Biogen Idec Ltd

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  5. 0.9% Sodium Chloride Solution, Glenzocimab

    Pari Pharma GmbH

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  6. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  7. 0.9% Sodium Chloride, JNJ-78901563

    Janssen Pharmaceutica N.V.

    Invasive Extraintestinal Pathogenic Escherichia coli Disease

    phase 3 small molecule active

    1 trial

  8. 0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  9. 0.9% sodium chloride, GB-0895

    Generate Biomedicines

    severe uncontrolled asthma

    phase 3 small molecule active

    1 trial

  10. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial

  11. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  12. 1% Clascoterone Cream

    Sunshine Biopharma

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  13. 1.0% C31G SAVVY vaginal gel

    United Therapeutics Europe Ltd

    HIV Infections

    phase 3 small molecule active

    2 trials

  14. 1.0mg/kg/day PRAX-562

    PRECISION BIOSCIENCES INC

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial

  15. 10-week smoking cessation group therapy combined with NicoDerm CQ

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 3 other completed

    1 trial

  16. 11C-SB207145, 11C-DASB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Parkinson's disease, Prodromal phase of Parkinson's disease

    phase 3 small molecule active

    1 trial

  17. 12-Valent Pneumococcal Conjugate Vaccine

    MAIA Biotechnology

    Pneumococcal Vaccines

    phase 3 mab active

    1 trial

  18. 131I-apamistamab

    Actinium Pharmaceuticals

    Acute Leukemia

    phase 3 small molecule active

    1 trial

  19. 177Lu-TLX250

    Telix Innovations

    ccRCC

    phase 3 other active

    1 trial

  20. 177Lu-TLX591

    Telix Innovations

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  21. 18F fluciclovine

    PRECISION BIOSCIENCES INC

    Brain Metastases

    phase 3 small molecule completed

    2 trials

  22. 18F-AV-1451

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Maladie d' Alzheimer, Alzheimer's pathology

    phase 3 small molecule active

    1 trial

  23. 18F-DPA-714

    Pari Pharma GmbH

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

  24. 18F-LBT-999

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Comatose Traumatic Brain Injury patients

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources